Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07545122). This is a study registration, not published results. Lead sponsor: Context Therapeutics Inc.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 162 participants (ESTIMATED). Conditions: Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer. Interventions: DRUG: CT-202. Primary outcome measures: Phase 1a: Incidence of Dose Limiting Toxicities (DLTs) , From date of first dose of CT-202 until 28 days following the first dose; Phase 1b: Overall response rate (ORR) , From date of first dose of CT-202until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months. Brief summary: This is a Phase 1a/1b, first time in human (FTIH), open-label, dose escalation and expansion study to evaluate the safety, tolerability, and preliminary efficacy of CT-202 (study drug), a humanized T cell engaging bispecific antibody targeting nectin-4, in participants with nectin-4 expressing recurrent, unresectable or metastatic refractory/resistant TNBC, CRC, or UC. Results of the study including PK, PD, efficacy, and safety will be used in the RP2D determination.